Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 14/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | METTL14 | Q9HCE5 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918948 | 0.86 | METTL3 (0.54) | METTL3PRKDCKDM4EMAPTHPGD | |
| SCHEMBL31015578 | 0.83 | KDM4E (0.43) | KDM4EMAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL22499335 | 0.81 | KDM4E (0.57) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL24691325 | 0.79 | KDM4E (0.56) | METTL3KDM4EMAPTHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL22499322 | 0.79 | KDM4E (0.56) | METTL3KDM4EMAPTHPGDKMT2A | |
| Lithium Ion SCHEMBL22499045 | 0.78 | METTL3 (0.53) | METTL3PRKDCKDM4EMAPTHPGD | |
| SCHEMBL3958034 | 0.76 | KDM4E (0.55) | METTL3PRKDCKDM4EMAPTHPGD | |
| SCHEMBL823315 | 0.76 | ALDH1A1 (0.56) | METTL3KDM4EMAPTHPGDKMT2A | |
| SCHEMBL862066 | 0.75 | KDM4E (0.51) | METTL3PRKDCKDM4EMAPTHPGD | |
| SCHEMBL30132372 | 0.72 | PKM (0.57) | METTL3PRKDCKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | claimed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | claimed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | METTL3 1/4885PRKDC 2082/4885KDM4E 872/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | METTL3 1/4885PRKDC 2082/4885KDM4E 872/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | METTL3 1/4885PRKDC 2082/4885KDM4E 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.